Correlation between the simultaneus expression of HER2 and PTEN and the risk of development of metastasis in NSCLC

A. Stamatelopoulos, E. Tsiambas, N. Atzoulatos, P. Michos, I. Gakidis, D. Bouros (Athens, Alexandroupolis, Greece)

Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Session: Pathology and prognostic factors of thoracic tumours
Session type: Poster Discussion
Number: 509
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Stamatelopoulos, E. Tsiambas, N. Atzoulatos, P. Michos, I. Gakidis, D. Bouros (Athens, Alexandroupolis, Greece). Correlation between the simultaneus expression of HER2 and PTEN and the risk of development of metastasis in NSCLC. Eur Respir J 2014; 44: Suppl. 58, 509

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Investigation of survivin gene expression in non small cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014

Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014


Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014


Gene expression of EGFR, MINA53,MEN1 and MTOR in NSCLCs
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014


MET genetic lesions in NSCLC are functional markers of early hematogenous spreading and radioresistance
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015


The roles of Ki-67, p53, transforming growth factor- and lysyl oxidase in the metastasis of lung cancer
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014


Prognostic value and functional characterization of miR-141 and miR-200c expression levels in resected NSCL
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014


The prognostic impact of PD1 and PDL1 expression in non-small cell lung cancer
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015

Immunohistochemical expression of nuclear factor kappa-B/p65 and cyclooxygenase-2 in non-small cell lung cancer patients: Prognostic value and impact on survival
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014


beta-F1-ATPase expression as a prognostic factor for resected non-small cell lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013

Potential genetic markers for the early diagnosis of peripheral and metastatic lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015


Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016


Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016

Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014

Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013

Breast metastasis from primary EGFR-mutated lung carcinoma or primary tumor?
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016


Prognostic value of EGFR mutation in NSCLC in surgical stage
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014

Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013


mRNA biomarker screening in pulmonary tumors showing neuroendocrine differentiation
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013


Comprehensive evaluation of nuclear factor-κΒ expression patterns in non-small cell lung cancer
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015